<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1998-12-15" modified="2017-12-20" version="202">
<accession>Q16678</accession>
<accession>Q5TZW8</accession>
<accession>Q93089</accession>
<accession>Q9H316</accession>
<name>CP1B1_HUMAN</name>
<protein>
<recommendedName>
<fullName>Cytochrome P450 1B1</fullName>
<ecNumber evidence="4 27">1.14.14.1</ecNumber>
</recommendedName>
<alternativeName>
<fullName>CYPIB1</fullName>
</alternativeName>
</protein>
<gene>
<name type="primary">CYP1B1</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="13092" last="13099">
<title>Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2.</title>
<authorList>
<person name="Sutter T.R."/>
<person name="Tang Y.M."/>
<person name="Hayes C.L."/>
<person name="Wo Y.-Y.P."/>
<person name="Jabs E.W."/>
<person name="Li X."/>
<person name="Yin H."/>
<person name="Cody C.W."/>
<person name="Greenlee W.F."/>
</authorList>
<dbReference type="PubMed" id="8175734"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>INDUCTION</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1996" name="J. Biol. Chem." volume="271" first="28324" last="28330">
<title>Isolation and characterization of the human cytochrome P450 CYP1B1 gene.</title>
<authorList>
<person name="Tang Y.M."/>
<person name="Wo Y.-Y.P."/>
<person name="Stewart J."/>
<person name="Hawkins A.L."/>
<person name="Griffin C.A."/>
<person name="Sutter T.R."/>
<person name="Greenlee W.F."/>
</authorList>
<dbReference type="PubMed" id="8910454"/>
<dbReference type="DOI" id="10.1074/jbc.271.45.28324"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
</reference>
<reference key="3">
<citation type="submission" date="2001-11" db="EMBL/GenBank/DDBJ databases">
<title>Physical/genetic map of the 2p22-2p21 region on chromosome 2.</title>
<authorList>
<person name="Gorry M.C."/>
<person name="Zhang Y."/>
<person name="Marks J.J."/>
<person name="Suppe B."/>
<person name="Hart P.S."/>
<person name="Cortelli J.R."/>
<person name="Pallos D."/>
<person name="Hart T.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
</reference>
<reference key="4">
<citation type="submission" date="2004-10" db="EMBL/GenBank/DDBJ databases">
<title>Cloning of human full-length CDSs in BD Creator(TM) system donor vector.</title>
<authorList>
<person name="Kalnine N."/>
<person name="Chen X."/>
<person name="Rolfs A."/>
<person name="Halleck A."/>
<person name="Hines L."/>
<person name="Eisenstein S."/>
<person name="Koundinya M."/>
<person name="Raphael J."/>
<person name="Moreira D."/>
<person name="Kelley T."/>
<person name="LaBaer J."/>
<person name="Lin Y."/>
<person name="Phelan M."/>
<person name="Farmer A."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]</scope>
<scope>VARIANT SER-453</scope>
</reference>
<reference key="5">
<citation type="submission" date="2003-09" db="EMBL/GenBank/DDBJ databases">
<authorList>
<consortium name="NIEHS SNPs program"/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANTS GLY-48; SER-119; ASN-206; LEU-266; VAL-432 AND SER-453</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]</scope>
<source>
<tissue>Lung</tissue>
</source>
</reference>
<reference key="7">
<citation type="submission" date="1999-07" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Guillemette C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-112</scope>
<scope>VARIANT GLY-48</scope>
</reference>
<reference key="8">
<citation type="journal article" date="1999" name="Carcinogenesis" volume="20" first="1607" last="1613">
<title>Catalytic properties of polymorphic human cytochrome P450 1B1 variants.</title>
<authorList>
<person name="Shimada T."/>
<person name="Watanabe J."/>
<person name="Kawajiri K."/>
<person name="Sutter T.R."/>
<person name="Guengerich F.P."/>
<person name="Gillam E.M.J."/>
<person name="Inoue K."/>
</authorList>
<dbReference type="PubMed" id="10426814"/>
<dbReference type="DOI" id="10.1093/carcin/20.8.1607"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>BIOPHYSICOCHEMICAL PROPERTIES</scope>
<scope>CHARACTERIZATION OF VARIANTS SER-119 AND VAL-432</scope>
</reference>
<reference key="9">
<citation type="journal article" date="2001" name="J. Med. Genet." volume="38" first="324" last="326">
<title>Phenotypic heterogeneity of CYP1B1: mutations in a patient with Peters' anomaly.</title>
<authorList>
<person name="Vincent A."/>
<person name="Billingsley G."/>
<person name="Priston M."/>
<person name="Williams-Lyn D."/>
<person name="Sutherland J."/>
<person name="Glaser T."/>
<person name="Oliver E."/>
<person name="Walter M.A."/>
<person name="Heathcote G."/>
<person name="Levin A."/>
<person name="Heon E."/>
</authorList>
<dbReference type="PubMed" id="11403040"/>
<dbReference type="DOI" id="10.1136/jmg.38.5.324"/>
</citation>
<scope>INVOLVEMENT IN ASGD6</scope>
</reference>
<reference key="10">
<citation type="journal article" date="2004" name="Drug Metab. Dispos." volume="32" first="840" last="847">
<title>Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1.</title>
<authorList>
<person name="Choudhary D."/>
<person name="Jansson I."/>
<person name="Stoilov I."/>
<person name="Sarfarazi M."/>
<person name="Schenkman J.B."/>
</authorList>
<dbReference type="PubMed" id="15258110"/>
<dbReference type="DOI" id="10.1124/dmd.32.8.840"/>
</citation>
<scope>FUNCTION</scope>
<scope>BIOPHYSICOCHEMICAL PROPERTIES</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2012" name="J. Biochem." volume="152" first="433" last="442">
<title>Increase of human CYP1B1 activities by acidic phospholipids and kinetic deuterium isotope effects on CYP1B1 substrate oxidation.</title>
<authorList>
<person name="Jang H.H."/>
<person name="Kim S.Y."/>
<person name="Kang J.Y."/>
<person name="Park S.H."/>
<person name="Ryu S.H."/>
<person name="Ahn T."/>
<person name="Yun C.H."/>
</authorList>
<dbReference type="PubMed" id="22888116"/>
<dbReference type="DOI" id="10.1093/jb/mvs087"/>
</citation>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ENZYME REGULATION</scope>
<scope>FUNCTION</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2013" name="Mol. Pharmacol." volume="84" first="451" last="458">
<title>Specificity determinants of CYP1B1 estradiol hydroxylation.</title>
<authorList>
<person name="Nishida C.R."/>
<person name="Everett S."/>
<person name="Ortiz de Montellano P.R."/>
</authorList>
<dbReference type="PubMed" id="23821647"/>
<dbReference type="DOI" id="10.1124/mol.113.087700"/>
</citation>
<scope>MUTAGENESIS OF VAL-395</scope>
<scope>FUNCTION IN ESTROGEN METABOLISM</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2013" name="Br. J. Nutr." volume="109" first="1598" last="1605">
<title>The citrus flavanone naringenin suppresses CYP1B1 transactivation through antagonising xenobiotic-responsive element binding.</title>
<authorList>
<person name="Poon C.H."/>
<person name="Wong T.Y."/>
<person name="Wang Y."/>
<person name="Tsuchiya Y."/>
<person name="Nakajima M."/>
<person name="Yokoi T."/>
<person name="Leung L.K."/>
</authorList>
<dbReference type="PubMed" id="22935222"/>
<dbReference type="DOI" id="10.1017/S0007114512003595"/>
</citation>
<scope>ENZYME REGULATION</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2011" name="J. Biol. Chem." volume="286" first="5736" last="5743">
<title>Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1.</title>
<authorList>
<person name="Wang A."/>
<person name="Savas U."/>
<person name="Stout C.D."/>
<person name="Johnson E.F."/>
</authorList>
<dbReference type="PubMed" id="21147782"/>
<dbReference type="DOI" id="10.1074/jbc.M110.204420"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 51-543 IN COMPLEX WITH HEME AND THE INHIBITOR ALPHA-NAPHTOFLAVONE</scope>
<scope>COFACTOR</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1998" name="Am. J. Hum. Genet." volume="62" first="325" last="333">
<title>Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia.</title>
<authorList>
<person name="Bejjani B.A."/>
<person name="Lewis R.A."/>
<person name="Tomey K.F."/>
<person name="Anderson K.L."/>
<person name="Dueker D.K."/>
<person name="Jabak M."/>
<person name="Astle W.F."/>
<person name="Otterud B."/>
<person name="Leppert M."/>
<person name="Lupski J.R."/>
</authorList>
<dbReference type="PubMed" id="9463332"/>
<dbReference type="DOI" id="10.1086/301725"/>
</citation>
<scope>VARIANTS GLC3A GLU-61; ASN-374 AND TRP-469</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1998" name="Am. J. Hum. Genet." volume="62" first="573" last="584">
<title>Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1.</title>
<authorList>
<person name="Stoilov I."/>
<person name="Akarsu A.N."/>
<person name="Alozie I."/>
<person name="Child A."/>
<person name="Barsoum-Homsy M."/>
<person name="Turacli M.E."/>
<person name="Or M."/>
<person name="Lewis R.A."/>
<person name="Ozdemir N."/>
<person name="Brice G."/>
<person name="Aktan S.G."/>
<person name="Chevrette L."/>
<person name="Coca-Prados M."/>
<person name="Sarfarazi M."/>
</authorList>
<dbReference type="PubMed" id="9497261"/>
<dbReference type="DOI" id="10.1086/301764"/>
</citation>
<scope>VARIANT GLC3A TRP-365</scope>
<scope>VARIANTS CYS-57; GLU-61; TRP-365; LEU-379; LYS-387; HIS-390; VAL-432; LEU-437 AND TRP-469</scope>
</reference>
<reference key="17">
<citation type="journal article" date="1998" name="Cancer Res." volume="58" first="5038" last="5041">
<title>Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer.</title>
<authorList>
<person name="Bailey L.R."/>
<person name="Roodi N."/>
<person name="Dupont W.D."/>
<person name="Parl F.F."/>
</authorList>
<dbReference type="PubMed" id="9823305"/>
</citation>
<scope>VARIANTS VAL-432 AND SER-453</scope>
</reference>
<reference key="18">
<citation type="journal article" date="1999" name="Cancer Res." volume="59" first="1388" last="1388">
<authorList>
<person name="Bailey L.R."/>
<person name="Roodi N."/>
<person name="Dupont W.D."/>
<person name="Parl F.F."/>
</authorList>
</citation>
<scope>ERRATUM</scope>
</reference>
<reference key="19">
<citation type="journal article" date="1999" name="J. Med. Genet." volume="36" first="290" last="294">
<title>Identification of a single ancestral CYP1B1 mutation in Slovak Gypsies (Roms) affected with primary congenital glaucoma.</title>
<authorList>
<person name="Plasilova M."/>
<person name="Stoilov I."/>
<person name="Sarfarazi M."/>
<person name="Kadasi L."/>
<person name="Ferakova E."/>
<person name="Ferak V."/>
</authorList>
<dbReference type="PubMed" id="10227395"/>
</citation>
<scope>VARIANT GLC3A LYS-387</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2000" name="Hum. Mol. Genet." volume="9" first="367" last="374">
<title>Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novo events and a dominant modifier locus.</title>
<authorList>
<person name="Bejjani B.A."/>
<person name="Stockton D.W."/>
<person name="Lewis R.A."/>
<person name="Tomey K.F."/>
<person name="Dueker D.K."/>
<person name="Jabak M."/>
<person name="Astle W.F."/>
<person name="Lupski J.R."/>
</authorList>
<dbReference type="PubMed" id="10655546"/>
<dbReference type="DOI" id="10.1093/hmg/9.3.367"/>
</citation>
<scope>VARIANTS GLC3A GLU-61; PRO-77; 269-SER--PHE-271 DEL; HIS-368; ASN-374; SER-390 AND TRP-469</scope>
<scope>VARIANTS GLY-48; SER-119; VAL-432 AND SER-453</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2000" name="Hum. Mol. Genet." volume="9" first="1141" last="1141">
<authorList>
<person name="Bejjani B.A."/>
<person name="Stockton D.W."/>
<person name="Lewis R.A."/>
<person name="Tomey K.F."/>
<person name="Dueker D.K."/>
<person name="Jabak M."/>
<person name="Astle W.F."/>
<person name="Lupski J.R."/>
</authorList>
</citation>
<scope>ERRATUM</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2000" name="Ophthalmic Genet." volume="21" first="191" last="193">
<title>Novel compound heterozygous mutations in the cytochrome P4501B1 gene (CYP1B1) in a Japanese patient with primary congenital glaucoma.</title>
<authorList>
<person name="Ohtake Y."/>
<person name="Kubota R."/>
<person name="Tanino T."/>
<person name="Miyata H."/>
<person name="Mashima Y."/>
</authorList>
<dbReference type="PubMed" id="11184479"/>
<dbReference type="DOI" id="10.1076/1381-6810(200009)2131-ZFT191"/>
</citation>
<scope>VARIANT GLC3A MET-364</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2000" name="Pharmacogenetics" volume="10" first="25" last="33">
<title>Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer.</title>
<authorList>
<person name="Watanabe J."/>
<person name="Shimada T."/>
<person name="Gillam E.M."/>
<person name="Ikuta T."/>
<person name="Suemasu K."/>
<person name="Higashi Y."/>
<person name="Gotoh O."/>
<person name="Kawajiri K."/>
</authorList>
<dbReference type="PubMed" id="10739169"/>
<dbReference type="DOI" id="10.1097/00008571-200002000-00004"/>
</citation>
<scope>VARIANTS SER-119 AND VAL-432</scope>
<scope>ASSOCIATION WITH BREAST OR LUNG CANCER</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2001" name="Invest. Ophthalmol. Vis. Sci." volume="42" first="2211" last="2216">
<title>Novel cytochrome P4501B1 (CYP1B1) gene mutations in Japanese patients with primary congenital glaucoma.</title>
<authorList>
<person name="Mashima Y."/>
<person name="Suzuki Y."/>
<person name="Sergeev Y."/>
<person name="Ohtake Y."/>
<person name="Tanino T."/>
<person name="Kimura I."/>
<person name="Miyata H."/>
<person name="Aihara M."/>
<person name="Tanihara H."/>
<person name="Inatani M."/>
<person name="Azuma N."/>
<person name="Iwata T."/>
<person name="Araie M."/>
</authorList>
<dbReference type="PubMed" id="11527932"/>
</citation>
<scope>VARIANTS GLC3A VAL-192; ILE-198; LEU-320; PHE-330; MET-364; GLN-444 AND GLY-499</scope>
<scope>VARIANTS GLY-48; SER-119 AND VAL-432</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2001" name="Invest. Ophthalmol. Vis. Sci." volume="42" first="2775" last="2775">
<authorList>
<person name="Mashima Y."/>
<person name="Suzuki Y."/>
<person name="Sergeev Y."/>
<person name="Ohtake Y."/>
<person name="Tanino T."/>
<person name="Kimura I."/>
<person name="Miyata H."/>
<person name="Aihara M."/>
<person name="Tanihara H."/>
<person name="Inatani M."/>
<person name="Azuma N."/>
<person name="Iwata T."/>
<person name="Araie M."/>
</authorList>
</citation>
<scope>ERRATUM</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2002" name="Am. J. Hum. Genet." volume="70" first="448" last="460">
<title>Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene.</title>
<authorList>
<person name="Vincent A.L."/>
<person name="Billingsley G."/>
<person name="Buys Y."/>
<person name="Levin A.V."/>
<person name="Priston M."/>
<person name="Trope G."/>
<person name="Williams-Lyn D."/>
<person name="Heon E."/>
</authorList>
<dbReference type="PubMed" id="11774072"/>
<dbReference type="DOI" id="10.1086/338709"/>
</citation>
<scope>VARIANT POAG PHE-345</scope>
<scope>VARIANT GLC1A HIS-368</scope>
<scope>VARIANT VAL-432</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2002" name="Invest. Ophthalmol. Vis. Sci." volume="43" first="1358" last="1366">
<title>Identification of novel mutations causing familial primary congenital glaucoma in Indian pedigrees.</title>
<authorList>
<person name="Panicker S.G."/>
<person name="Reddy A.B.M."/>
<person name="Mandal A.K."/>
<person name="Ahmed N."/>
<person name="Nagarajaram H.A."/>
<person name="Hasnain S.E."/>
<person name="Balasubramanian D."/>
</authorList>
<dbReference type="PubMed" id="11980847"/>
</citation>
<scope>VARIANTS GLC3A GLU-61; LEU-193; LYS-229 AND HIS-368</scope>
<scope>VARIANTS GLY-48; SER-184 AND VAL-432</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2002" name="Invest. Ophthalmol. Vis. Sci." volume="43" first="1820" last="1827">
<title>Molecular genetics of primary congenital glaucoma in Brazil.</title>
<authorList>
<person name="Stoilov I.R."/>
<person name="Costa V.P."/>
<person name="Vasconcellos J.P.C."/>
<person name="Melo M.B."/>
<person name="Betinjane A.J."/>
<person name="Carani J.C.E."/>
<person name="Oltrogge E.V."/>
<person name="Sarfarazi M."/>
</authorList>
<dbReference type="PubMed" id="12036985"/>
</citation>
<scope>VARIANTS GLC3A HIS-368; LYS-387; LEU-437 AND GLY-443</scope>
<scope>VARIANTS GLY-48; SER-119; VAL-432 AND SER-453</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2002" name="Mol. Pharmacol." volume="61" first="586" last="594">
<title>Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population.</title>
<authorList>
<person name="Aklillu E."/>
<person name="Oscarson M."/>
<person name="Hidestrand M."/>
<person name="Leidvik B."/>
<person name="Otter C."/>
<person name="Ingelman-Sundberg M."/>
</authorList>
<dbReference type="PubMed" id="11854439"/>
<dbReference type="DOI" id="10.1124/mol.61.3.586"/>
</citation>
<scope>VARIANTS GLY-48; SER-119; VAL-432; GLY-443 AND SER-453</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2003" name="Hum. Genet." volume="113" first="556" last="558">
<title>Gene symbol: CYP1B1. Disease: glaucoma, primary congenital.</title>
<authorList>
<person name="Chakrabarti S."/>
<person name="Komatireddy S."/>
<person name="Mandal A.K."/>
<person name="Balasubramanian D."/>
</authorList>
<dbReference type="PubMed" id="14640114"/>
<dbReference type="DOI" id="10.1007/s00439-003-1035-0"/>
</citation>
<scope>VARIANTS GLC3A ARG-144 AND CYS-445</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2003" name="Hum. Mutat." volume="22" first="496" last="496">
<title>Novel cytochrome P450 1B1 (CYP1B1) mutations in patients with primary congenital glaucoma in France.</title>
<authorList>
<person name="Colomb E."/>
<person name="Kaplan J."/>
<person name="Garchon H.-J."/>
</authorList>
<dbReference type="PubMed" id="14635112"/>
<dbReference type="DOI" id="10.1002/humu.9197"/>
</citation>
<scope>VARIANTS GLC3A LYS-229; ARG-232; LYS-387; SER-390; SER-399 AND TYR-423</scope>
<scope>VARIANTS GLY-48; SER-119; VAL-432 AND SER-453</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2003" name="J. Med. Genet." volume="40" first="E9" last="E9">
<title>CYP1B1 gene analysis in primary congenital glaucoma in Indonesian and European patients.</title>
<authorList>
<person name="Sitorus R."/>
<person name="Ardjo S.M."/>
<person name="Lorenz B."/>
<person name="Preising M."/>
</authorList>
<dbReference type="PubMed" id="12525557"/>
<dbReference type="DOI" id="10.1136/jmg.40.1.e9"/>
</citation>
<scope>VARIANTS GLC3A ILE-215; 355-ARG--ALA-358 DEL AND MET-364</scope>
<scope>VARIANTS GLY-48; SER-119; VAL-432 AND SER-453</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2004" name="J. Med. Genet." volume="41" first="647" last="651">
<title>CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma.</title>
<authorList>
<person name="Melki R."/>
<person name="Colomb E."/>
<person name="Lefort N."/>
<person name="Brezin A.P."/>
<person name="Garchon H.-J."/>
</authorList>
<dbReference type="PubMed" id="15342693"/>
<dbReference type="DOI" id="10.1136/jmg.2004.020024"/>
</citation>
<scope>VARIANTS POAG ASN-81; LYS-229; ARG-232; SER-269--PHE-271 DEL; LYS-387; HIS-390; TYR-423 AND GLY-443</scope>
<scope>VARIANTS GLC3A ARG-232; LYS-387 AND TYR-423</scope>
<scope>VARIANTS GLY-48; SER119; VAL-432 AND SER-453</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2004" name="Mol. Vis." volume="10" first="696" last="702">
<title>Mutation spectrum of the CYP1B1 gene in Indian primary congenital glaucoma patients.</title>
<authorList>
<person name="Reddy A.B.M."/>
<person name="Kaur K."/>
<person name="Mandal A.K."/>
<person name="Panicker S.G."/>
<person name="Thomas R."/>
<person name="Hasnain S.E."/>
<person name="Balasubramanian D."/>
<person name="Chakrabarti S."/>
</authorList>
<dbReference type="PubMed" id="15475877"/>
</citation>
<scope>VARIANTS GLC3A PRO-77; PRO-115; ARG-132; PRO-144; LEU-193; LYS-229; ARG-239; HIS-368; HIS-390; CYS-390; LEU-437 AND ASP-466</scope>
<scope>VARIANTS GLY-48; SER-119; VAL-432 AND SER-453</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2004" name="Ophthalmic Genet." volume="25" first="3" last="9">
<title>Cytochrome P4501B1 mutations cause only part of primary congenital glaucoma in Ecuador.</title>
<authorList>
<person name="Curry S.M."/>
<person name="Daou A.G."/>
<person name="Hermanns P."/>
<person name="Molinari A."/>
<person name="Lewis R.A."/>
<person name="Bejjani B.A."/>
</authorList>
<dbReference type="PubMed" id="15255109"/>
<dbReference type="DOI" id="10.1076/opge.25.1.3.28999"/>
</citation>
<scope>VARIANT GLC3A CYS-390</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2006" name="Am. J. Ophthalmol." volume="141" first="512" last="516">
<title>Molecular and clinical evaluation of primary congenital glaucoma in Kuwait.</title>
<authorList>
<person name="Alfadhli S."/>
<person name="Behbehani A."/>
<person name="Elshafey A."/>
<person name="Abdelmoaty S."/>
<person name="Al-Awadi S."/>
</authorList>
<dbReference type="PubMed" id="16490498"/>
<dbReference type="DOI" id="10.1016/j.ajo.2005.11.001"/>
</citation>
<scope>VARIANTS GLC3A GLU-61; HIS-368 AND THR-388</scope>
<scope>VARIANT GLY-422</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2006" name="Mol. Vis." volume="12" first="399" last="404">
<title>Primary role of CYP1B1 in Indian juvenile-onset POAG patients.</title>
<authorList>
<person name="Acharya M."/>
<person name="Mookherjee S."/>
<person name="Bhattacharjee A."/>
<person name="Bandyopadhyay A.K."/>
<person name="Daulat Thakur S.K."/>
<person name="Bhaduri G."/>
<person name="Sen A."/>
<person name="Ray K."/>
</authorList>
<dbReference type="PubMed" id="16688110"/>
</citation>
<scope>VARIANTS POAG CYS-57; LYS-229; HIS-368; LEU-515; THR-523 AND GLY-530</scope>
<scope>VARIANTS GLY-48; SER-119; VAL-432; SER-453 AND ALA-518</scope>
</reference>
<reference key="38">
<citation type="journal article" date="2006" name="Mol. Vis." volume="12" first="523" last="531">
<title>Primary congenital glaucoma and Rieger's anomaly: extended haplotypes reveal founder effects for eight distinct CYP1B1 mutations.</title>
<authorList>
<person name="Chavarria-Soley G."/>
<person name="Michels-Rautenstrauss K."/>
<person name="Pasutto F."/>
<person name="Flikier D."/>
<person name="Flikier P."/>
<person name="Cirak S."/>
<person name="Bejjani B."/>
<person name="Winters D.L."/>
<person name="Lewis R.A."/>
<person name="Mardin C."/>
<person name="Reis A."/>
<person name="Rautenstrauss B."/>
</authorList>
<dbReference type="PubMed" id="16735994"/>
</citation>
<scope>VARIANTS GLC3A GLU-61; ASN-81; LYS-229; LEU-343 DEL; HIS-368; LYS-387 AND TRP-469</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2006" name="Mol. Vis." volume="12" first="748" last="755">
<title>Heterozygous CYP1B1 gene mutations in Spanish patients with primary open-angle glaucoma.</title>
<authorList>
<person name="Lopez-Garrido M.-P."/>
<person name="Sanchez-Sanchez F."/>
<person name="Lopez-Martinez F."/>
<person name="Aroca-Aguilar J.-D."/>
<person name="Blanco-Marchite C."/>
<person name="Coca-Prados M."/>
<person name="Escribano J."/>
</authorList>
<dbReference type="PubMed" id="16862072"/>
</citation>
<scope>VARIANTS POAG TRP-28; GLU-61; ASN-81; TRP-145; LYS-229; PHE-409 AND GLY-443</scope>
<scope>VARIANTS LEU-52; HIS-144; PRO-189 AND SER-330</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2008" name="Hum. Mutat." volume="29" first="1147" last="1153">
<title>Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme.</title>
<authorList>
<person name="Chavarria-Soley G."/>
<person name="Sticht H."/>
<person name="Aklillu E."/>
<person name="Ingelman-Sundberg M."/>
<person name="Pasutto F."/>
<person name="Reis A."/>
<person name="Rautenstrauss B."/>
</authorList>
<dbReference type="PubMed" id="18470941"/>
<dbReference type="DOI" id="10.1002/humu.20786"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS GLC3A GLU-61; SER-203; LYS-229 AND LEU-343 DEL</scope>
<scope>CHARACTERIZATION OF VARIANT POAG ASN-81</scope>
</reference>
<comment type="function">
<text evidence="4 18 27 29">Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compounds to their activated forms, including polycyclic aromatic hydrocarbons. Promotes angiogenesis by removing cellular oxygenation products, thereby decreasing oxidative stress, release of antiangiogenic factor THBS2, then allowing endothelial cells migration, cell adhesion and capillary morphogenesis. These changes are concommitant with the endothelial nitric oxide synthase activity and nitric oxide synthesis. Plays an important role in the regulation of perivascular cell proliferation, migration, and survival through modulation of the intracellular oxidative state and NF-kappa-B expression and/or activity, during angiogenesis. Contributes to oxidative homeostasis and ultrastructural organization and function of trabecular meshwork tissue through modulation of POSTN expression.</text>
</comment>
<comment type="catalytic activity">
<text evidence="4 27">RH + [reduced NADPH--hemoprotein reductase] + O(2) = ROH + [oxidized NADPH--hemoprotein reductase] + H(2)O.</text>
</comment>
<comment type="cofactor">
<cofactor evidence="26">
<name>heme</name>
<dbReference type="ChEBI" id="CHEBI:30413"/>
</cofactor>
</comment>
<comment type="enzyme regulation">
<text evidence="27 28">Enzyme activity is increased by liposomes containing anionic phospholipids, phosphatidic acid and cardiolipin. Inhibited by naringenin with an IC(50) of 5 uM.</text>
</comment>
<comment type="biophysicochemical properties">
<kinetics>
<KM evidence="4 18">6.0 uM for 17-beta-estradiol</KM>
<KM evidence="4 18">17.0 uM for testosterone</KM>
<KM evidence="4 18">24.0 uM for progesterone</KM>
<KM evidence="4 18">18.5 uM for retinol</KM>
<KM evidence="4 18">8.5 uM for retinal</KM>
<KM evidence="4 18">29.8 uM for arachidonic acid</KM>
<KM evidence="4 18">212.8 uM for 7,12-dimethyltetraphene</KM>
<Vmax evidence="4 18">14.95 nmol/min/mg enzyme for 17-beta-estradiol 4-hydroxylation</Vmax>
<Vmax evidence="4 18">6.9 nmol/min/mg enzyme for 17-beta-estradiol 2-hydroxylation</Vmax>
<Vmax evidence="4 18">36.16 nmol/min/mg enzyme for testosterone 6-beta-hydroxylation</Vmax>
<Vmax evidence="4 18">9.86 nmol/min/mg enzyme for progesterone 6-beta-hydroxylation</Vmax>
<Vmax evidence="4 18">37.80 nmol/min/mg enzyme for progesterone 16-alpha-hydroxylation</Vmax>
<text>kcat is 0.15 min(-1) for retinol, 0.77 min(-1) for retinal, 2.86 min(-1) for 7,12-dimethyltetraphene, 0.48 min(-1) for arachidonic acid.</text>
</kinetics>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location>Endoplasmic reticulum membrane</location>
<topology>Peripheral membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location>Microsome membrane</location>
<topology>Peripheral membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location evidence="2">Mitochondrion</location>
</subcellularLocation>
</comment>
<comment type="tissue specificity">
<text evidence="30">Expressed in many tissues.</text>
</comment>
<comment type="induction">
<text evidence="30">By polycyclic aromatic hydrocarbons (PAH) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).</text>
</comment>
<comment type="polymorphism">
<text>Various CYP1B1 alleles are known. The sequence shown is that of allele CYP1B1*1.</text>
</comment>
<comment type="disease" evidence="8">
<disease id="DI-04923">
<name>Anterior segment dysgenesis 6</name>
<acronym>ASGD6</acronym>
<description>A form of anterior segment dysgenesis, a group of defects affecting anterior structures of the eye including cornea, iris, lens, trabecular meshwork, and Schlemm canal. Anterior segment dysgeneses result from abnormal migration or differentiation of the neural crest derived mesenchymal cells that give rise to components of the anterior chamber during eye development. Different anterior segment anomalies may exist alone or in combination, including iris hypoplasia, enlarged or reduced corneal diameter, corneal vascularization and opacity, posterior embryotoxon, corectopia, polycoria, abnormal iridocorneal angle, ectopia lentis, and anterior synechiae between the iris and posterior corneal surface. Clinical conditions falling within the phenotypic spectrum of anterior segment dysgeneses include aniridia, Axenfeld anomaly, Reiger anomaly/syndrome, Peters anomaly, and iridogoniodysgenesis. ASGD6 patients predominantly manifest Peters anomaly. Peters anomaly consists of corneal leukoma, defects in the posterior structures of the cornea such as absence of the posterior corneal stroma and Descemet membrane, and a variable degree of iridocorneal and/or keratolenticular adhesions. Over 50% of patients develop glaucoma in childhood.</description>
<dbReference type="MIM" id="617315"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="3 5 7 9 12 13 14 15 16 17 19 20 21 23 25 31 32">
<disease id="DI-00935">
<name>Glaucoma 3, primary congenital, A</name>
<acronym>GLC3A</acronym>
<description>An autosomal recessive form of primary congenital glaucoma (PCG). PCG is characterized by marked increase of intraocular pressure at birth or early childhood, large ocular globes (buphthalmos) and corneal edema. It results from developmental defects of the trabecular meshwork and anterior chamber angle of the eye that prevent adequate drainage of aqueous humor.</description>
<dbReference type="MIM" id="231300"/>
</disease>
<text>The disease is caused by mutations affecting distinct genetic loci, including the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="10 19 22 24 25">
<disease id="DI-00936">
<name>Glaucoma, primary open angle</name>
<acronym>POAG</acronym>
<description>A complex and genetically heterogeneous ocular disorder characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. In some cases, POAG shows digenic inheritance involving mutations in CYP1B1 and MYOC genes.</description>
<dbReference type="MIM" id="137760"/>
</disease>
<text evidence="19">Disease susceptibility is associated with variations affecting the gene represented in this entry. CYP1B1 mutations have been reported to pose a significant risk for early-onset POAG and also modify glaucoma phenotype in patients who do not carry a MYOC mutation (PubMed:15342693).</text>
</comment>
<comment type="disease" evidence="10">
<disease id="DI-00937">
<name>Glaucoma 1, open angle, A</name>
<acronym>GLC1A</acronym>
<description>A form of primary open angle glaucoma (POAG). POAG is characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. However, glaucoma can occur at any intraocular pressure. The disease is generally asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place.</description>
<dbReference type="MIM" id="137750"/>
</disease>
<text evidence="10">The gene represented in this entry acts as a disease modifier. Digenic mutations in CYP1B1 and MYOC have been found in a family segregating both primary adult-onset and juvenile forms of open angle glaucoma (PubMed:11774072). All affected family members with mutations in both MYOC and CYP1B1 had juvenile glaucoma, whereas those with only the MYOC mutation had the adult-onset form (PubMed:11774072).</text>
</comment>
<comment type="similarity">
<text evidence="37">Belongs to the cytochrome P450 family.</text>
</comment>
<comment type="online information" name="Cytochrome P450 Allele Nomenclature Committee">
<link uri="http://www.cypalleles.ki.se/cyp1b1.htm"/>
<text>CYP1B1 alleles</text>
</comment>
<comment type="online information" name="NIEHS-SNPs">
<link uri="http://egp.gs.washington.edu/data/cyp1b1/"/>
</comment>
<dbReference type="EC" id="1.14.14.1" evidence="4 27"/>
<dbReference type="EMBL" id="U03688">
<property type="protein sequence ID" value="AAA19567.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="U56438">
<property type="protein sequence ID" value="AAC50809.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AF450132">
<property type="protein sequence ID" value="AAM50512.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AF450131">
<property type="protein sequence ID" value="AAM50512.1"/>
<property type="status" value="JOINED"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BT019979">
<property type="protein sequence ID" value="AAV38782.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AY393998">
<property type="protein sequence ID" value="AAQ87875.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC012049">
<property type="protein sequence ID" value="AAH12049.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF171066">
<property type="protein sequence ID" value="AAG43404.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS1793.1"/>
<dbReference type="PIR" id="A54116">
<property type="entry name" value="A54116"/>
</dbReference>
<dbReference type="RefSeq" id="NP_000095.2">
<property type="nucleotide sequence ID" value="NM_000104.3"/>
</dbReference>
<dbReference type="UniGene" id="Hs.154654"/>
<dbReference type="PDB" id="3PM0">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A=51-543"/>
</dbReference>
<dbReference type="PDBsum" id="3PM0"/>
<dbReference type="ProteinModelPortal" id="Q16678"/>
<dbReference type="SMR" id="Q16678"/>
<dbReference type="BioGrid" id="107925">
<property type="interactions" value="2"/>
</dbReference>
<dbReference type="IntAct" id="Q16678">
<property type="interactions" value="2"/>
</dbReference>
<dbReference type="STRING" id="9606.ENSP00000260630"/>
<dbReference type="BindingDB" id="Q16678"/>
<dbReference type="ChEMBL" id="CHEMBL4878"/>
<dbReference type="DrugBank" id="DB02342">
<property type="generic name" value="2-Methoxyestradiol"/>
</dbReference>
<dbReference type="DrugBank" id="DB00613">
<property type="generic name" value="Amodiaquine"/>
</dbReference>
<dbReference type="DrugBank" id="DB01169">
<property type="generic name" value="Arsenic trioxide"/>
</dbReference>
<dbReference type="DrugBank" id="DB00121">
<property type="generic name" value="Biotin"/>
</dbReference>
<dbReference type="DrugBank" id="DB00201">
<property type="generic name" value="Caffeine"/>
</dbReference>
<dbReference type="DrugBank" id="DB00363">
<property type="generic name" value="Clozapine"/>
</dbReference>
<dbReference type="DrugBank" id="DB01254">
<property type="generic name" value="Dasatinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB00694">
<property type="generic name" value="Daunorubicin"/>
</dbReference>
<dbReference type="DrugBank" id="DB01234">
<property type="generic name" value="Dexamethasone"/>
</dbReference>
<dbReference type="DrugBank" id="DB01248">
<property type="generic name" value="Docetaxel"/>
</dbReference>
<dbReference type="DrugBank" id="DB00997">
<property type="generic name" value="Doxorubicin"/>
</dbReference>
<dbReference type="DrugBank" id="DB00530">
<property type="generic name" value="Erlotinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB00783">
<property type="generic name" value="Estradiol"/>
</dbReference>
<dbReference type="DrugBank" id="DB00655">
<property type="generic name" value="Estrone"/>
</dbReference>
<dbReference type="DrugBank" id="DB00499">
<property type="generic name" value="Flutamide"/>
</dbReference>
<dbReference type="DrugBank" id="DB01026">
<property type="generic name" value="Ketoconazole"/>
</dbReference>
<dbReference type="DrugBank" id="DB00448">
<property type="generic name" value="Lansoprazole"/>
</dbReference>
<dbReference type="DrugBank" id="DB01065">
<property type="generic name" value="Melatonin"/>
</dbReference>
<dbReference type="DrugBank" id="DB01204">
<property type="generic name" value="Mitoxantrone"/>
</dbReference>
<dbReference type="DrugBank" id="DB00338">
<property type="generic name" value="Omeprazole"/>
</dbReference>
<dbReference type="DrugBank" id="DB00526">
<property type="generic name" value="Oxaliplatin"/>
</dbReference>
<dbReference type="DrugBank" id="DB01229">
<property type="generic name" value="Paclitaxel"/>
</dbReference>
<dbReference type="DrugBank" id="DB01174">
<property type="generic name" value="Phenobarbital"/>
</dbReference>
<dbReference type="DrugBank" id="DB01087">
<property type="generic name" value="Primaquine"/>
</dbReference>
<dbReference type="DrugBank" id="DB01168">
<property type="generic name" value="Procarbazine"/>
</dbReference>
<dbReference type="DrugBank" id="DB00396">
<property type="generic name" value="Progesterone"/>
</dbReference>
<dbReference type="DrugBank" id="DB00818">
<property type="generic name" value="Propofol"/>
</dbReference>
<dbReference type="DrugBank" id="DB02709">
<property type="generic name" value="Resveratrol"/>
</dbReference>
<dbReference type="DrugBank" id="DB00675">
<property type="generic name" value="Tamoxifen"/>
</dbReference>
<dbReference type="DrugBank" id="DB00624">
<property type="generic name" value="Testosterone"/>
</dbReference>
<dbReference type="DrugBank" id="DB00277">
<property type="generic name" value="Theophylline"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1320"/>
<dbReference type="SwissLipids" id="SLP:000001331"/>
<dbReference type="iPTMnet" id="Q16678"/>
<dbReference type="PhosphoSitePlus" id="Q16678"/>
<dbReference type="BioMuta" id="CYP1B1"/>
<dbReference type="DMDM" id="48429256"/>
<dbReference type="EPD" id="Q16678"/>
<dbReference type="MaxQB" id="Q16678"/>
<dbReference type="PaxDb" id="Q16678"/>
<dbReference type="PeptideAtlas" id="Q16678"/>
<dbReference type="PRIDE" id="Q16678"/>
<dbReference type="DNASU" id="1545"/>
<dbReference type="Ensembl" id="ENST00000610745">
<property type="protein sequence ID" value="ENSP00000478561"/>
<property type="gene ID" value="ENSG00000138061"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000614273">
<property type="protein sequence ID" value="ENSP00000483678"/>
<property type="gene ID" value="ENSG00000138061"/>
</dbReference>
<dbReference type="GeneID" id="1545"/>
<dbReference type="KEGG" id="hsa:1545"/>
<dbReference type="UCSC" id="uc032njx.2">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="1545"/>
<dbReference type="DisGeNET" id="1545"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000138061.11"/>
<dbReference type="GeneCards" id="CYP1B1"/>
<dbReference type="GeneReviews" id="CYP1B1"/>
<dbReference type="H-InvDB" id="HIX0001979"/>
<dbReference type="HGNC" id="HGNC:2597">
<property type="gene designation" value="CYP1B1"/>
</dbReference>
<dbReference type="HPA" id="CAB011705"/>
<dbReference type="HPA" id="HPA026863"/>
<dbReference type="MalaCards" id="CYP1B1"/>
<dbReference type="MIM" id="137750">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="137760">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="231300">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="601771">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="617315">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_Q16678"/>
<dbReference type="OpenTargets" id="ENSG00000138061"/>
<dbReference type="Orphanet" id="98976">
<property type="disease" value="Congenital glaucoma"/>
</dbReference>
<dbReference type="Orphanet" id="98977">
<property type="disease" value="Juvenile glaucoma"/>
</dbReference>
<dbReference type="Orphanet" id="708">
<property type="disease" value="Peters anomaly"/>
</dbReference>
<dbReference type="Orphanet" id="353225">
<property type="disease" value="Primary adult open-angle glaucoma"/>
</dbReference>
<dbReference type="PharmGKB" id="PA27094"/>
<dbReference type="eggNOG" id="KOG0156">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG2124">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00900000140831"/>
<dbReference type="HOGENOM" id="HOG000036991"/>
<dbReference type="HOVERGEN" id="HBG106944"/>
<dbReference type="InParanoid" id="Q16678"/>
<dbReference type="KO" id="K07410"/>
<dbReference type="OMA" id="AVCFGCR"/>
<dbReference type="OrthoDB" id="EOG091G0BT8"/>
<dbReference type="PhylomeDB" id="Q16678"/>
<dbReference type="TreeFam" id="TF105095"/>
<dbReference type="BioCyc" id="MetaCyc:HS06443-MONOMER"/>
<dbReference type="Reactome" id="R-HSA-211976">
<property type="pathway name" value="Endogenous sterols"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2142670">
<property type="pathway name" value="Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2142816">
<property type="pathway name" value="Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5579000">
<property type="pathway name" value="Defective CYP1B1 causes Glaucoma"/>
</dbReference>
<dbReference type="SABIO-RK" id="Q16678"/>
<dbReference type="SIGNOR" id="Q16678"/>
<dbReference type="ChiTaRS" id="CYP1B1">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="Q16678"/>
<dbReference type="GeneWiki" id="CYP1B1"/>
<dbReference type="GenomeRNAi" id="1545"/>
<dbReference type="PRO" id="PR:Q16678"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 2"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000138061"/>
<dbReference type="CleanEx" id="HS_CYP1B1"/>
<dbReference type="ExpressionAtlas" id="Q16678">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="Q16678">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005789">
<property type="term" value="C:endoplasmic reticulum membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043231">
<property type="term" value="C:intracellular membrane-bounded organelle"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0005739">
<property type="term" value="C:mitochondrion"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031090">
<property type="term" value="C:organelle membrane"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0070330">
<property type="term" value="F:aromatase activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-EC"/>
</dbReference>
<dbReference type="GO" id="GO:0020037">
<property type="term" value="F:heme binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005506">
<property type="term" value="F:iron ion binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0004497">
<property type="term" value="F:monooxygenase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016712">
<property type="term" value="F:oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0019825">
<property type="term" value="F:oxygen binding"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001525">
<property type="term" value="P:angiogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0019369">
<property type="term" value="P:arachidonic acid metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048514">
<property type="term" value="P:blood vessel morphogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007155">
<property type="term" value="P:cell adhesion"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006725">
<property type="term" value="P:cellular aromatic compound metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0070301">
<property type="term" value="P:cellular response to hydrogen peroxide"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0071407">
<property type="term" value="P:cellular response to organic cyclic compound"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="MGI"/>
</dbReference>
<dbReference type="GO" id="GO:0030199">
<property type="term" value="P:collagen fibril organization"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043542">
<property type="term" value="P:endothelial cell migration"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0071603">
<property type="term" value="P:endothelial cell-cell adhesion"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0019373">
<property type="term" value="P:epoxygenase P450 pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0008210">
<property type="term" value="P:estrogen metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008631">
<property type="term" value="P:intrinsic apoptotic signaling pathway in response to oxidative stress"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046466">
<property type="term" value="P:membrane lipid catabolic process"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0033629">
<property type="term" value="P:negative regulation of cell adhesion mediated by integrin"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030336">
<property type="term" value="P:negative regulation of cell migration"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008285">
<property type="term" value="P:negative regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032088">
<property type="term" value="P:negative regulation of NF-kappaB transcription factor activity"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006809">
<property type="term" value="P:nitric oxide biosynthetic process"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0097267">
<property type="term" value="P:omega-hydroxylase P450 pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0055114">
<property type="term" value="P:oxidation-reduction process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045766">
<property type="term" value="P:positive regulation of angiogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043065">
<property type="term" value="P:positive regulation of apoptotic process"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046427">
<property type="term" value="P:positive regulation of JAK-STAT cascade"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010575">
<property type="term" value="P:positive regulation of vascular endothelial growth factor production"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000377">
<property type="term" value="P:regulation of reactive oxygen species metabolic process"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0009636">
<property type="term" value="P:response to toxic substance"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0061304">
<property type="term" value="P:retinal blood vessel morphogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042574">
<property type="term" value="P:retinal metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042572">
<property type="term" value="P:retinol metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008202">
<property type="term" value="P:steroid metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016125">
<property type="term" value="P:sterol metabolic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0009404">
<property type="term" value="P:toxin metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0002930">
<property type="term" value="P:trabecular meshwork development"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007601">
<property type="term" value="P:visual perception"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0006805">
<property type="term" value="P:xenobiotic metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="Gene3D" id="1.10.630.10">
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR032971">
<property type="entry name" value="CYP1B1"/>
</dbReference>
<dbReference type="InterPro" id="IPR001128">
<property type="entry name" value="Cyt_P450"/>
</dbReference>
<dbReference type="InterPro" id="IPR017972">
<property type="entry name" value="Cyt_P450_CS"/>
</dbReference>
<dbReference type="InterPro" id="IPR002401">
<property type="entry name" value="Cyt_P450_E_grp-I"/>
</dbReference>
<dbReference type="InterPro" id="IPR036396">
<property type="entry name" value="Cyt_P450_sf"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR24299:SF2">
<property type="entry name" value="PTHR24299:SF2"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF00067">
<property type="entry name" value="p450"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00463">
<property type="entry name" value="EP450I"/>
</dbReference>
<dbReference type="PRINTS" id="PR00385">
<property type="entry name" value="P450"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF48264">
<property type="entry name" value="SSF48264"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00086">
<property type="entry name" value="CYTOCHROME_P450"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0256">Endoplasmic reticulum</keyword>
<keyword id="KW-0955">Glaucoma</keyword>
<keyword id="KW-0349">Heme</keyword>
<keyword id="KW-0408">Iron</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0492">Microsome</keyword>
<keyword id="KW-0496">Mitochondrion</keyword>
<keyword id="KW-0503">Monooxygenase</keyword>
<keyword id="KW-0560">Oxidoreductase</keyword>
<keyword id="KW-1059">Peters anomaly</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<feature type="chain" description="Cytochrome P450 1B1" id="PRO_0000051660">
<location>
<begin position="1"/>
<end position="543"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Iron (heme axial ligand)" evidence="1 26">
<location>
<position position="470"/>
</location>
</feature>
<feature type="site" description="Major determinant of CYP1B1 17beta-estradiol hydroxylation regiospecificity">
<location>
<position position="395"/>
</location>
</feature>
<feature type="sequence variant" description="In POAG; dbSNP:rs780002791." id="VAR_054227" evidence="24">
<original>S</original>
<variation>W</variation>
<location>
<position position="28"/>
</location>
</feature>
<feature type="sequence variant" description="In allele CYP1B1*2, allele CYP1B1*5, allele CYP1B1*6 and allele CYP1B1*7; dbSNP:rs10012." id="VAR_011752" evidence="5 9 11 12 13 14 15 19 20 22 35 36">
<original>R</original>
<variation>G</variation>
<location>
<position position="48"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs201824781." id="VAR_054228" evidence="24">
<original>P</original>
<variation>L</variation>
<location>
<position position="52"/>
</location>
</feature>
<feature type="sequence variant" description="In POAG; juvenile onset; allele CYP1B1*11; dbSNP:rs72549387." id="VAR_008350" evidence="22 32">
<original>W</original>
<variation>C</variation>
<location>
<position position="57"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A and POAG; allele CYP1B1*12; reduces enzymatic activity; dbSNP:rs28936700." id="VAR_001244" evidence="5 12 21 23 24 25 31 32">
<original>G</original>
<variation>E</variation>
<location>
<position position="61"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs9282670." id="VAR_028735">
<original>Q</original>
<variation>R</variation>
<location>
<position position="68"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A." id="VAR_054229" evidence="5 20">
<original>L</original>
<variation>P</variation>
<location>
<position position="77"/>
</location>
</feature>
<feature type="sequence variant" description="In POAG; adult-onset; hypomorphic allele; reduces the abundance of the enzyme; dbSNP:rs9282671." id="VAR_028736" evidence="19 23 24 25">
<original>Y</original>
<variation>N</variation>
<location>
<position position="81"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs764338357." id="VAR_054230" evidence="20">
<original>A</original>
<variation>P</variation>
<location>
<position position="115"/>
</location>
</feature>
<feature type="sequence variant" description="In allele CYP1B1*2, allele CYP1B1*6 and allele CYP1B1*7; significantly associated with breast or lung cancer; no significant change in 17beta-estradiol 2- and 4-hydroxylation activities and 17beta-estradiol affinity; 1.5-fold reduction in testosterone affinity but nearly no change in testosterone 6beta-hydroxylation activity; 2-fold increase in progesterone 6beta- and 16alpha-hydroxylation activities and 5-fold reduction in progesterone affinity; dbSNP:rs1056827." id="VAR_011753" evidence="4 5 6 9 11 13 14 15 20 22 35">
<original>A</original>
<variation>S</variation>
<location>
<position position="119"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A." id="VAR_054231" evidence="20">
<original>M</original>
<variation>R</variation>
<location>
<position position="132"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_054232" evidence="24">
<original>Q</original>
<variation>H</variation>
<location>
<position position="144"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A." id="VAR_054233" evidence="20">
<original>Q</original>
<variation>P</variation>
<location>
<position position="144"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs753847648." id="VAR_054234" evidence="16">
<original>Q</original>
<variation>R</variation>
<location>
<position position="144"/>
</location>
</feature>
<feature type="sequence variant" description="In POAG." id="VAR_054235" evidence="24">
<original>R</original>
<variation>W</variation>
<location>
<position position="145"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_054236" evidence="12">
<original>G</original>
<variation>S</variation>
<location>
<position position="184"/>
</location>
</feature>
<feature type="sequence variant" description="Associated with ocular hypertension susceptibility." id="VAR_054237" evidence="24">
<original>A</original>
<variation>P</variation>
<location>
<position position="189"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A." id="VAR_054238" evidence="9">
<original>D</original>
<variation>V</variation>
<location>
<position position="192"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs529769268." id="VAR_054239" evidence="12 20">
<original>P</original>
<variation>L</variation>
<location>
<position position="193"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs59472972." id="VAR_054240" evidence="9">
<original>V</original>
<variation>I</variation>
<location>
<position position="198"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; reduces enzymatic activity." id="VAR_054241" evidence="25">
<original>N</original>
<variation>S</variation>
<location>
<position position="203"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs9341248." id="VAR_018869" evidence="35">
<original>S</original>
<variation>N</variation>
<location>
<position position="206"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs72549384." id="VAR_054242" evidence="14">
<original>S</original>
<variation>I</variation>
<location>
<position position="215"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A and POAG; juvenile-onset; hypomorphic allele; reduces the abundance of the enzyme; dbSNP:rs57865060." id="VAR_054243" evidence="12 15 19 20 22 23 24 25">
<original>E</original>
<variation>K</variation>
<location>
<position position="229"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A and POAG; adult-onset; dbSNP:rs104893628." id="VAR_054244" evidence="15 19">
<original>G</original>
<variation>R</variation>
<location>
<position position="232"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A." id="VAR_054245" evidence="20">
<original>S</original>
<variation>R</variation>
<location>
<position position="239"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs9341250." id="VAR_018870" evidence="35">
<original>R</original>
<variation>L</variation>
<location>
<position position="266"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A and POAG." id="VAR_054246" evidence="5">
<location>
<begin position="269"/>
<end position="271"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs72549382." id="VAR_054247" evidence="9">
<original>V</original>
<variation>L</variation>
<location>
<position position="320"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; requires 2 nucleotide substitutions; unknown pathological significance." id="VAR_054248" evidence="9">
<original>A</original>
<variation>F</variation>
<location>
<position position="330"/>
</location>
</feature>
<feature type="sequence variant" description="Associated with ocular hypertension susceptibility." id="VAR_054249" evidence="24">
<original>A</original>
<variation>S</variation>
<location>
<position position="330"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; reduces enzymatic activity and also the abundance of the enzyme." id="VAR_054250" evidence="23 25">
<location>
<position position="343"/>
</location>
</feature>
<feature type="sequence variant" description="In POAG; dbSNP:rs66583685." id="VAR_054251" evidence="10">
<original>L</original>
<variation>F</variation>
<location>
<position position="345"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A." id="VAR_054252" evidence="14">
<location>
<begin position="355"/>
<end position="358"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs72549379." id="VAR_054253" evidence="7 9 14">
<original>V</original>
<variation>M</variation>
<location>
<position position="364"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; allele CYP1B1*18; dbSNP:rs55771538." id="VAR_001245" evidence="32">
<original>G</original>
<variation>W</variation>
<location>
<position position="365"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A and GLC1A; acts as GLC1A disease modifier in patients also carrying Val-399 mutation in MYOC; dbSNP:rs79204362." id="VAR_016034" evidence="5 10 12 13 20 21 22 23">
<original>R</original>
<variation>H</variation>
<location>
<position position="368"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs104893622." id="VAR_001246" evidence="5 31">
<original>D</original>
<variation>N</variation>
<location>
<position position="374"/>
</location>
</feature>
<feature type="sequence variant" description="In allele CYP1B1*19; dbSNP:rs56305281." id="VAR_008351" evidence="32">
<original>P</original>
<variation>L</variation>
<location>
<position position="379"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A and POAG; allele CYP1B1*20; dbSNP:rs55989760." id="VAR_008352" evidence="3 13 15 19 23 32">
<original>E</original>
<variation>K</variation>
<location>
<position position="387"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A." id="VAR_054254" evidence="21">
<original>A</original>
<variation>T</variation>
<location>
<position position="388"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs148542782." id="VAR_054255" evidence="17 20">
<original>R</original>
<variation>C</variation>
<location>
<position position="390"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; allele CYP1B1*21; dbSNP:rs56010818." id="VAR_008353" evidence="19 20 32">
<original>R</original>
<variation>H</variation>
<location>
<position position="390"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs148542782." id="VAR_054256" evidence="5 15">
<original>R</original>
<variation>S</variation>
<location>
<position position="390"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs72549378." id="VAR_054257" evidence="15">
<original>I</original>
<variation>S</variation>
<location>
<position position="399"/>
</location>
</feature>
<feature type="sequence variant" description="In POAG; dbSNP:rs957253424." id="VAR_054258" evidence="24">
<original>V</original>
<variation>F</variation>
<location>
<position position="409"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_054259" evidence="21">
<original>V</original>
<variation>G</variation>
<location>
<position position="422"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A and POAG; juvenile-onset; dbSNP:rs104893629." id="VAR_054260" evidence="15 19">
<original>N</original>
<variation>Y</variation>
<location>
<position position="423"/>
</location>
</feature>
<feature type="sequence variant" description="In allele CYP1B1*3, allele CYP1B1*5, allele CYP1B1*6 and allele CYP1B1*7; 1.6-fold increase in 17beta-estradiol 4-hydroxylation activity but no change in 17beta-estradiol 2-hydroxylation activity; 2-fold reduction in testosterone 6beta-hydroxylation activity and 3-fold reduction in testosterone affinity; 6-fold and 4-fold increase in progesterone 6beta- and 16alpha-hydroxylation activity, respectively and 7-fold reduction in progesterone affinity; dbSNP:rs1056836." id="VAR_001248" evidence="4 5 6 9 10 11 12 13 14 15 19 20 22 32 33 35">
<original>L</original>
<variation>V</variation>
<location>
<position position="432"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; allele CYP1B1*23; dbSNP:rs56175199." id="VAR_008354" evidence="13 20 32">
<original>P</original>
<variation>L</variation>
<location>
<position position="437"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs4986887." id="VAR_028737">
<original>D</original>
<variation>H</variation>
<location>
<position position="441"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A and POAG; allele CYP1B1*7; unknown pathological significance; dbSNP:rs4986888." id="VAR_018774" evidence="11 13 19 24">
<original>A</original>
<variation>G</variation>
<location>
<position position="443"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs72549376." id="VAR_054261" evidence="9">
<original>R</original>
<variation>Q</variation>
<location>
<position position="444"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A." id="VAR_054262" evidence="16">
<original>F</original>
<variation>C</variation>
<location>
<position position="445"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs1056837." id="VAR_028738">
<original>D</original>
<variation>E</variation>
<location>
<position position="449"/>
</location>
</feature>
<feature type="sequence variant" description="In allele CYP1B1*4; dbSNP:rs1800440." id="VAR_008355" evidence="5 11 13 14 15 19 20 22 33 34 35">
<original>N</original>
<variation>S</variation>
<location>
<position position="453"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs868208502." id="VAR_054263" evidence="20">
<original>G</original>
<variation>D</variation>
<location>
<position position="466"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; allele CYP1B1*25; dbSNP:rs28936701." id="VAR_001247" evidence="5 23 31 32">
<original>R</original>
<variation>W</variation>
<location>
<position position="469"/>
</location>
</feature>
<feature type="sequence variant" description="In GLC3A; dbSNP:rs72549372." id="VAR_054264" evidence="9">
<original>E</original>
<variation>G</variation>
<location>
<position position="499"/>
</location>
</feature>
<feature type="sequence variant" description="In POAG; unknown pathological significance." id="VAR_054265" evidence="22">
<original>S</original>
<variation>L</variation>
<location>
<position position="515"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_054266" evidence="22">
<original>V</original>
<variation>A</variation>
<location>
<position position="518"/>
</location>
</feature>
<feature type="sequence variant" description="In POAG; juvenile-onset." id="VAR_054267" evidence="22">
<original>R</original>
<variation>T</variation>
<location>
<position position="523"/>
</location>
</feature>
<feature type="sequence variant" description="In POAG." id="VAR_054268" evidence="22">
<original>D</original>
<variation>G</variation>
<location>
<position position="530"/>
</location>
</feature>
<feature type="mutagenesis site" description="Invertes the 4OH E2:2OH E2 hydroxylation preference from 5.1 to 0.45." evidence="29">
<original>V</original>
<variation>L</variation>
<location>
<position position="395"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="70"/>
<end position="81"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="83"/>
<end position="89"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="92"/>
<end position="97"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="100"/>
<end position="107"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="108"/>
<end position="113"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="121"/>
<end position="125"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="126"/>
<end position="129"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="132"/>
<end position="135"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="139"/>
<end position="154"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="162"/>
<end position="183"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="184"/>
<end position="188"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="194"/>
<end position="209"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="219"/>
<end position="224"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="228"/>
<end position="235"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="241"/>
<end position="243"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="245"/>
<end position="249"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="253"/>
<end position="282"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="292"/>
<end position="304"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="317"/>
<end position="319"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="320"/>
<end position="348"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="350"/>
<end position="363"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="372"/>
<end position="377"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="379"/>
<end position="392"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="407"/>
<end position="409"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="412"/>
<end position="414"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="419"/>
<end position="424"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="425"/>
<end position="428"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="431"/>
<end position="433"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="435"/>
<end position="439"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="442"/>
<end position="445"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="454"/>
<end position="457"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="473"/>
<end position="490"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="491"/>
<end position="495"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="505"/>
<end position="513"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="518"/>
<end position="524"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="3PM0"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000250"/>
<evidence key="3" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10227395"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10426814"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10655546"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10739169"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11184479"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11403040"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11527932"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11774072"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11854439"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11980847"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12036985"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12525557"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14635112"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14640114"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15255109"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15258110"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15342693"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15475877"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16490498"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16688110"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16735994"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16862072"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18470941"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="21147782"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22888116"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22935222"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23821647"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8175734"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9463332"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9497261"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9823305"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source ref="4"/>
</evidence>
<evidence key="35" type="ECO:0000269">
<source ref="5"/>
</evidence>
<evidence key="36" type="ECO:0000269">
<source ref="7"/>
</evidence>
<evidence key="37" type="ECO:0000305"/>
<sequence length="543" mass="60846" checksum="46B6DA7368F63EA2" modified="2004-06-07" version="2">
MGTSLSPNDPWPLNPLSIQQTTLLLLLSVLATVHVGQRLLRQRRRQLRSAPPGPFAWPLI
GNAAAVGQAAHLSFARLARRYGDVFQIRLGSCPIVVLNGERAIHQALVQQGSAFADRPAF
ASFRVVSGGRSMAFGHYSEHWKVQRRAAHSMMRNFFTRQPRSRQVLEGHVLSEARELVAL
LVRGSADGAFLDPRPLTVVAVANVMSAVCFGCRYSHDDPEFRELLSHNEEFGRTVGAGSL
VDVMPWLQYFPNPVRTVFREFEQLNRNFSNFILDKFLRHCESLRPGAAPRDMMDAFILSA
EKKAAGDSHGGGARLDLENVPATITDIFGASQDTLSTALQWLLLLFTRYPDVQTRVQAEL
DQVVGRDRLPCMGDQPNLPYVLAFLYEAMRFSSFVPVTIPHATTANTSVLGYHIPKDTVV
FVNQWSVNHDPLKWPNPENFDPARFLDKDGLINKDLTSRVMIFSVGKRRCIGEELSKMQL
FLFISILAHQCDFRANPNEPAKMNFSYGLTIKPKSFKVNVTLRESMELLDSAVQNLQAKE
TCQ
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>